title: Effect of Serial Intrasilicone Oil Bevacizumab Injections in Eyes With Recurrent Proliferative Vitreoretinopathy Retinal Detachment.
abstract: OBJECTIVE
  To investigate the effect of serial intrasilicone oil bevacizumab injections (1.25 mg/0.05 mL) on visual acuity (VA) and anatomic outcomes in eyes undergoing proliferative vitreoretinopathy (PVR)-related retinal detachment (RD) repair.
  
  
  METHODS
  Prospective, nonrandomized, historical-control pilot study.
  
  
  METHODS
  setting: Tertiary care center.
  
  
  METHODS
  Nondiabetic eyes undergoing pars plana vitrectomy (PPV) and silicone oil tamponade with or without scleral buckling procedure (SBP) for recurrent RD due to PVR.
  
  
  METHODS
  Intrasilicone oil injection of 1.25 mg bevacizumab was performed intraoperatively and at postoperative months 1, 2, and 3.
  
  
  RESULTS
  Retinal reattachment rate, final VA, and rate of epiretinal membrane (ERM) formation at month 6.
  
  
  RESULTS
  Twenty eyes of 20 patients were enrolled and compared to a historical control group composed of 35 age- and sex-matched controls. In the study group, logMAR VA improved from mean 1.78 ± 0.43 (Snellen 20/1205) to 1.43 ± 0.70 (Snellen 20/538, P = .04), retinal reattachment was achieved in 14 of 20 eyes (70%), and ERM formation was observed in 7 of 20 eyes (35%) at 6 months. In the control group, logMAR VA improved from mean 1.50 ± 0.74 (Snellen 20/632) to 1.43 ± 0.58 (Snellen 20/538, P = .64), retinal reattachment was achieved in 25 of 35 eyes (71%), and ERM formation was observed in 7 of 35 eyes (20%) at 6 months. No significant difference in final VA (P = .96), retinal reattachment rate (P = .75), or ERM formation (P = .33) was observed between groups. No intrasilicone oil injection-related adverse events occurred.
  
  
  CONCLUSIONS
  Serial intrasilicone oil injections of bevacizumab did not improve retinal reattachment rate, improve final VA, or reduce ERM formation in patients undergoing PVR-related RD surgery.
authors.affiliation: The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania. Electronic address: jhsu@midatlanticretina.com.
authors.forename: Jason
authors.initials: J
authors.lastname: Hsu
authors.affiliation: The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania.
authors.forename: M Ali
authors.initials: MA
authors.lastname: Khan
authors.affiliation: The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania.
authors.forename: Wen-Shi
authors.initials: WS
authors.lastname: Shieh
authors.affiliation: The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania.
authors.forename: Allen
authors.initials: A
authors.lastname: Chiang
authors.affiliation: The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania.
authors.forename: Joseph I
authors.initials: JI
authors.lastname: Maguire
authors.affiliation: The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania.
authors.forename: Carl H
authors.initials: CH
authors.lastname: Park
authors.affiliation: The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania.
authors.forename: Sunir J
authors.initials: SJ
authors.lastname: Garg
authors.affiliation: The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania.
authors.forename: Allen C
authors.initials: AC
authors.lastname: Ho
authors.affiliation: The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania.
authors.forename: Richard S
authors.initials: RS
authors.lastname: Kaiser
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D058450:Endotamponade; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D012008:Recurrence; D012163:Retinal Detachment / Q000503:physiopathology / Q000601:surgery*; D012827:Silicone Oils / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D014821:Vitrectomy; D018630:Vitreoretinopathy, Proliferative / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D012827:Silicone Oils; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab